CHMP Welcomes New Member from Greece
Dimitrios Kouvelas, PhD, has replaced Aikaterini Moraiti, PhD
Dimitrios Kouvelas, PhD, has replaced Aikaterini Moraiti, PhD, as Greece’s new member of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
Kouvelas is a professor of pharmacology and clinical pharmacology at the Aristotle School of Medicine, University of Thessaloniki, and a visiting professor of pharmacology and clinical pharmacology, University Svetozar Markovic Medical Faculty, Kraguijevac, Serbia. His research fields include neuro/psychopharmacology, neuro-transmission, clinical pharmacology and rational prescribing.
Moraiti has been a member of the CHMP since 2012, and is a scientific expert for Greece’s National Organization of Medicines and a member of the Greek Committee for Orphan Medicines.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
